1. Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma
   Joseph R. Fuchs et al, 2023, Frontiers in Oncology CrossRef
2. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
   Matthieu Roulleaux Dugage et al, 2021, Frontiers in Immunology CrossRef
3. Maximizing Immunotherapy in Sarcoma Using Histology, Biomarkers and Novel Approaches
   Jacob N Stein et al, 2022, Oncology & Haematology CrossRef
4. Systems-Level Mapping of Cancer Testis Antigen 1b/a to Sarcoma Pathways Identifies Activated Ran Binding-2 E3 SUMO-Protein Ligase and Transducin-Like Enhancer Protein 1
   Nikolaos A. Papanikolaou et al, 2022, Frontiers in Genetics CrossRef
5. High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
   Patrick Groothuis et al, 2021, Cancers CrossRef
6. The Sarcoma Immune Landscape: Emerging Challenges, Prognostic Significance and Prospective Impact for Immunotherapy Approaches
   Anna Koumarianou et al, 2021, Cancers CrossRef
7. NY-ESO-1 antigen-antibody interaction process based on an TFBG plasmonic sensor
   Hang Qu et al, 2023, Biomedical Optics Express CrossRef
8. Cancer Testis Antigens and Immunotherapy: Expression of PRAME Is Associated with Prognosis in Soft Tissue Sarcoma
   Markus Albertsmeier et al, 2020, Cancers CrossRef
9. Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas
   Kazuhiko Hashimoto et al, 2022, Diagnostics CrossRef
10. Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas
    Kazuhiko Hashimoto et al, 2022, European Journal of Histochemistry CrossRef
11. Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
    Philippe Rochigneux et al, 2021, Cancers CrossRef